IMAX Corporation (USA) (IMAX), Constellation Brands, Inc. (STZ): Three Predictions for Next Week

I’m going to stick with this pick. Most of the names in the composite are just too cheap at this point, and tech should be what carries us through the economic recovery. The market is ripe for the tech-stacked secondary stocks to continue to outpace the 30 megacaps that make up the Dow Jones Industrial Average (INDEXDJX:.DJI).

3.Peregrine Pharmaceuticals will beat Wall Street’s earnings estimates
Some stocks are just flat-out better than others.

Peregrine Pharmaceuticals (NASDAQ:PPHM) is an upstart biotech targeting the treatment and diagnosis of cancer through monoclonal antibodies. It has a potential winner in its lead candidate that will begin its telltale phase 3 clinical trial later this year.

Another thing it does is make analysts look like perpetual underachievers. If analysts say the company posted a loss of $0.06 a share in its latest quarter, I’ll argue that it held up better than that. History’s on my side!

One of my best tricks to beating the market is finding stocks that perpetually land ahead of the prognosticators. Let’s go over the past year of earnings reports.

Quarter	EPS Estimate	EPS	Surprise
Q4 2012	($0.13)	($0.10)	23%
Q1 2013	($0.11)	($0.07)	36%
Q2 2013	($0.09)	($0.08)	11%
Q3 2013	($0.07)	($0.04)	43%

Source: Thomson Reuters.

Things can change, of course. Despite posting lower deficits with every passing a quarter — a welcome trend in and of itself in eyeing the loss that analysts are forecasting — it’s certainly not cheap to ramp up pivotal late-stage clinical trials.

However, it’s hard to argue against the trend. Everything seems to be falling into place for another market-thumping quarter on the bottom line.

Three for the road
Well, there are three predictions right there. Let’s see how I fare this week.

The article 3 Predictions for Next Week originally appeared on Fool.com is written by Rick Munarriz.

Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends and owns shares of IMAX.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.